Aktie A14T7Q 3SBIO INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen 3SBio Inc.

Aktien

A14T7Q

KYG8875G1029

1530

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:09:00 03.05.2024 		% 5 Tage % 1. Jan.
6.8 HKD +3.34% Intraday Chart für 3SBio Inc. +18.67% -9.57%
22.04. 3Sbio Inc. kündigt Änderungen im Management an CI
12.04. 3SBio Inc. Zulassung der rekombinanten humanen Thrombopoietin-Injektion (Tpiao) für die pädiatrische ITP-Indikation CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
3Sbio Inc. Announces Management Changes
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product
Mandi Foam of 3SBio Inc. Approves for Market Launch
Venus Medtech Names Former 3SBio Finance Chief as CFO
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
3SBio : 2023 Interim Results Presentation
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
3SBio Hires Former JPMorgan Exec as CFO
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer
3SBio Rolls Out Pruritus Medication in China
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14T7Q Aktie
  4. Nachrichten 3SBio Inc.
  5. Andere Sprachen